Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development
Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Caris with an upfront payment as well as research funding.
- Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Caris with an upfront payment as well as research funding.
- Merck KGaA, Darmstadt, Germany will receive an exclusive global license to develop, manufacture and commercialize ADC therapeutics for selected targets.
- Caris Discovery leverages the scale of Caris' core molecular profiling business to discover novel, druggable targets that would be otherwise inaccessible through more traditional approaches.
- "We are proud to be working closely with Merck KGaA, Darmstadt, Germany, to bring new therapeutic options to cancer patients together."